Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1729-1736

  Targher, Giovanni ^a   Mantovani, Alessandro ^a   Pichiri, Isabella ^a   Mingolla, Lucia ^a   Cavalieri, Valentina ^a   Mantovani, William ^b,c   Pancheri, Serena ^b,c   Trombetta, Maddalena ^a   Zoppini, Giacomo ^a   Choncho, Michel ^a,d   Byrne, Christopher D ^e   Bonora, Enzo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Public Health Department   (Italy)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; COMPLICATION; DIABETES COMPLICATIONS; EPIDEMIOLOGY; ITALY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ADULT; ALBUMINURIA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84901462957     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2704     Document Type: Article

References (36)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023
2. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98:483-495
3. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30: 1212-1218
4. Williamson RM, Price JF, Glancy S, et al.; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139-1144
5. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131
6. Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010;53:713-718
7. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of cardiovascular disease in type 1 diabetic patients with nonalcoholic fatty liver disease. J Endocrinol Invest 2012;35:535-540
8. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344
9. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-1350
10. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-1200
11. TargherG, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011;54:1020-1029
12. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010;375:1296-1309
13. Castro AF, Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53(Suppl. 3): S46-S55
14. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives -a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247-259
15. Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010;53: 1341-1348
16. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver. Diabet Med 2012;29: 220-226
17. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/lasertreated retinopathy in type 2 diabetic patients. Diabetologia 2008;51:444-450
18. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19:1564-1570
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
20. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612
21. American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013;36(Suppl 1):S11-S66
22. Girman CJ, Rhodes T, Mercuri M, et al.; 4S Group and the AFCAPS/TexCAPS Research Group. Themetabolic syndrome and risk ofmajor coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-141
23. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008;14:3476-3483
24. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212
25. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001;60:2041-2055
26. Schjoedt KJ, Hansen HP, Tarnow L, Rossing P, Parving HH. Long-term prevention of diabetic nephropathy: an audit. Diabetologia 2008;51: 956-961
27. Vlagopoulos PT, Sarnak MJ. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005;89:587-611
28. Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 2012;7:401-408
29. Chang Y, Ryu S, Sung E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008;57:569-576
30. Lee DH, Jacobs DR Jr., Gross M, Steffes M. Serum gamma- glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2005;51:1185-1191
31. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. Gamma-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007;53:71-77
32. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9:372-381
33. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I,MuggeoM. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009;35:277-287
34. Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol 2013; 9:144-152
35. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009;5:677-689
36. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(Suppl. 2):S12-S154